IsoRay (ISR) Given a $1.00 Price Target at HC Wainwright

HC Wainwright set a $1.00 price objective on IsoRay (NYSEAMERICAN:ISR) in a research report report published on Thursday. The brokerage currently has a buy rating on the healthcare company’s stock.

ISR has been the subject of a number of other research reports. Zacks Investment Research downgraded shares of IsoRay from a hold rating to a sell rating in a research report on Wednesday. Maxim Group downgraded shares of IsoRay from a buy rating to a hold rating in a research report on Friday, November 9th.

Get IsoRay alerts:

NYSEAMERICAN:ISR traded up $0.02 during trading hours on Thursday, reaching $0.41. The company had a trading volume of 1,600 shares, compared to its average volume of 227,713. IsoRay has a 52 week low of $0.27 and a 52 week high of $1.22.

IsoRay (NYSEAMERICAN:ISR) last posted its earnings results on Tuesday, February 12th. The healthcare company reported ($0.02) EPS for the quarter, hitting analysts’ consensus estimates of ($0.02). The company had revenue of $1.90 million during the quarter, compared to the consensus estimate of $1.76 million.

Several hedge funds have recently modified their holdings of the company. Highland Private Wealth Management purchased a new position in shares of IsoRay during the 4th quarter valued at $39,000. Vanguard Group Inc. lifted its stake in shares of IsoRay by 24.7% during the 3rd quarter. Vanguard Group Inc. now owns 1,857,268 shares of the healthcare company’s stock valued at $964,000 after buying an additional 367,324 shares in the last quarter. Finally, Vanguard Group Inc lifted its stake in shares of IsoRay by 24.7% during the 3rd quarter. Vanguard Group Inc now owns 1,857,268 shares of the healthcare company’s stock valued at $964,000 after buying an additional 367,324 shares in the last quarter.

About IsoRay

IsoRay, Inc, through its subsidiary, IsoRay Medical, Inc, develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States. The company produces CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers, as well as ocular melanoma.

Featured Story: Analyzing a company’s cash flow statement

Leave a Reply

Your email address will not be published. Required fields are marked *